Vorinostat restores iNKT cell functionality in aggressive cholangiocarcinoma

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Invariant natural killer T (iNKT) cells possess anti-tumor properties but are often impaired in the tumor microenvironment.
• Cholangiocarcinoma (CCA) cell lines lacking CD1d molecules significantly reduce iNKT cell reactivity.
• Histone deacetylase (HDAC) inhibitors are being investigated for their immunomodulatory potential.

Purpose of the Study:

• To investigate the efficacy of HDAC inhibitors, specifically Vorinostat, in restoring iNKT cell functionality against CCA.
• To understand the molecular mechanisms by which Vorinostat impacts iNKT cell-CCA interactions.

Main Methods:

• Utilized aggressive CCA cell lines lacking CD1d molecules and invariant natural killer T (iNKT) cells.
• Employed the L1000FWD search engine to identify potential therapeutic agents.
• Assessed changes in CD1d expression, cytokine production, and T cell receptor (TCR) signaling pathways.
• Evaluated tumor growth inhibition in a mouse xenograft model.

Main Results:

• Vorinostat treatment enhanced CD1d expression and inflammatory cytokine production in CCA cells.
• Vorinostat reactivated iNKT cells by restoring TCR signaling pathways.
• Combined Vorinostat treatment significantly inhibited tumor growth in a preclinical mouse model.
• Vorinostat mitigated the decline in iNKT cell reactivity upon exposure to CCA cells.

Conclusions:

• Vorinostat demonstrates potential in restoring iNKT cell anti-tumor functionality in the context of CCA.
• Vorinostat may serve as a novel therapeutic strategy for cholangiocarcinoma, particularly in cases resistant to conventional chemotherapy.